The creation of an antithrombotic surface by apyrase immobilization.
暂无分享,去创建一个
[1] C. Alessandri,et al. Development of new antithrombogenic surfaces by employing platelet antiaggregating agents: preparation and characterization. , 1979, Transactions - American Society for Artificial Internal Organs.
[2] B. van der Lei,et al. Reduced thrombogenicity of artificial materials by coating with ADPase. , 1991, Biomaterials.
[3] A. Kastrati,et al. Time Course of Restenosis During the First Year After Emergency Coronary Stenting , 1993, Circulation.
[4] A. Marcus,et al. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. , 1997, The Journal of clinical investigation.
[5] ChristianGachet,et al. ADP Receptors and Clinical Bleeding Disorders , 1999 .
[6] B. Nilsson,et al. A new in vitro model to study interaction between whole blood and biomaterials. Studies of platelet and coagulation activation and the effect of aspirin. , 1999, Biomaterials.
[7] K. Clemetson,et al. The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. , 2000, Blood.
[8] S. Diamond,et al. Neutrophil Enhancement of Fibrin Deposition Under Flow Through Platelet-Dependent and -Independent Mechanisms , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[9] B. Nilsson,et al. Contact between a polymer and whole blood: sequence of events leading to thrombin generation. , 2001, The Journal of laboratory and clinical medicine.
[10] Yuan Zhang,et al. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. , 2002, The Journal of clinical investigation.
[11] G. Elgue,et al. Measuring the degree of plasma contact activation induced by artificial materials. , 2002, Thrombosis research.
[12] Thomas M. Smith,et al. Cloning, expression, and characterization of a soluble calcium-activated nucleotidase, a human enzyme belonging to a new family of extracellular nucleotidases. , 2002, Archives of biochemistry and biophysics.
[13] R. Busto,et al. Neuroprotective Effect of SolCD 39 , a Novel Platelet Aggregation Inhibitor , on Transient Middle Cerebral Artery Occlusion in Rats , 2003 .
[14] R. Busto,et al. Neuroprotective Effect of SolCD39, a Novel Platelet Aggregation Inhibitor, on Transient Middle Cerebral Artery Occlusion in Rats , 2003, Stroke.
[15] Thomas M. Smith,et al. Structure and Protein Design of a Human Platelet Function Inhibitor , 2004, Cell.
[16] Michael V Sefton,et al. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. , 2004, Biomaterials.
[17] M. J. Broekman,et al. Role of CD39 (NTPDase-1) in Thromboregulation, Cerebroprotection, and Cardioprotection , 2005, Seminars in thrombosis and hemostasis.
[18] M. J. Broekman,et al. Effects of SolCD39, a Novel Inhibitor of Platelet Aggregation, on Platelet Deposition and Aggregation after PTCA in a Porcine Model , 2005, Journal of Thrombosis and Thrombolysis.
[19] B. Nilsson,et al. Surface-attached PEO in the form of activated Pluronic with immobilized factor H reduces both coagulation and complement activation in a whole-blood model. , 2006, Journal of biomedical materials research. Part A.
[20] B. Nilsson,et al. Complement and coagulation: strangers or partners in crime? , 2007, Trends in immunology.
[21] John D Lambris,et al. Complement activation triggered by chondroitin sulfate released by thrombin receptor‐activated platelets , 2008, Journal of thrombosis and haemostasis : JTH.
[22] R. Lai,et al. Antihemostatic molecules from saliva of blood-feeding arthropods , 2008 .
[23] Anna E. Engberg,et al. Inhibition of complement activation on a model biomaterial surface by streptococcal M protein-derived peptides. , 2009, Biomaterials.
[24] Bo Nilsson,et al. Distinctive regulation of contact activation by antithrombin and C1-inhibitor on activated platelets and material surfaces. , 2009, Biomaterials.
[25] John D Lambris,et al. Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition? , 2010, Trends in immunology.